Daratumumab-based therapies in patients with AL amyloidosis.

被引：0
|
作者：
Abeykoon, Jithma P.
Zanwar, Saurabh
Kumar, Shaji
Dispenzieri, Angela
Rajkumar, S. Vincent
Lacy, Martha
Dingli, David
Leung, Nelson
Muchtar, Eli
Gonsalves, Wilson I.
Kourelis, Taxiarchis
Buadi, Francis
Kyle, Robert A.
Gertz, Morie A.
Kapoor, Prashant
机构：
[1] Mayo Clin, Dept Internal Med, Rochester, MN USA
[2] Mayo Clin, Rochester, MN USA
[3] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8053
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase II trial of lenalidomide for patients with AL amyloidosis.
    Sanchorawala, V.
    Wright, D. G.
    Rosenzweig, M.
    Finn, K. T.
    Skinner, M.
    Seldin, D. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 428S - 428S
  • [22] Amyloid deposits in the bone marrow in patients with AL amyloidosis.
    Scaramucci, L
    Niscola, P
    Ciafrino, R
    Morucci, M
    Montanaro, M
    BLOOD, 2003, 102 (11) : 365B - 365B
  • [23] HGF Measurement in AL Amyloidosis.
    Abraham, Julie
    Desport, Estelle
    Marin, Benoit
    Bender, Sebastien
    Lacombe, Corinne
    Girault, Stephane
    Moreau, Stephane
    Yagoubi, Fatima
    Bordessoule, Dominique
    Bridoux, Franck
    Jaccard, Arnaud
    BLOOD, 2009, 114 (22) : 709 - 709
  • [24] Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance
    Kastritis, Efstathios
    Theodorakakou, Foteini
    Roussou, Maria
    Psimenou, Erasmia
    Gakiopoulou, Charikleia
    Marinaki, Smaragdi
    Gatou, Anastasia
    Fotiou, Despina
    Migkou, Magdalini
    Kanellias, Nikolaos
    Eleutherakis-Papaiakovou, Evangelos
    Malandrakis, Panagiotis
    Dialoupi, Ioanna
    Ntanasis-Stathopoulos, Ioannis
    Kostopoulos, Ioannis, V
    Terpos, Evangelos
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (01) : 113 - 118
  • [25] Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.
    Lachmann, HJ
    Booth, DR
    Booth, SE
    Bybee, A
    Gilbertson, JA
    Gillmore, JD
    Pepys, MB
    Hawkins, PN
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (23): : 1786 - 1791
  • [26] Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis
    Rosko, Nathaniel
    Mo, Hanjie
    Rudoni, Joslyn
    Siebenaller, Caitlin
    Lee, Sarah S.
    Chakraborty, Rajshekar
    Faiman, Beth M.
    Khouri, Jack
    Garcia, Alex V. Mejia
    Samaras, Christy J.
    Anwer, Faiz
    Valent, Jason
    BLOOD, 2019, 134
  • [27] Daratumumab for the treatment of AL amyloidosis
    Sidiqi, M. Hasib
    Gertz, Morie A.
    LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 295 - 301
  • [28] Melphalan, Lenalidomide, and Dexamethasone Combination Therapy in Patients with AL Amyloidosis.
    Sloan, John Mark
    Sanchorawala, Vaishali
    Girnius, Saulius
    Finn, Kathleen T.
    Seldin, David C.
    BLOOD, 2009, 114 (22) : 737 - 738
  • [29] Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy
    Khan, Sahar
    Vaisman, Alon
    Hota, Susy S.
    Bennett, Sabrina
    Trudel, Suzanne
    Reece, Donna
    Tiedemann, Rodger E.
    JAMA ONCOLOGY, 2020, 6 (02) : 293 - 294
  • [30] Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy
    Dima, Danai
    Hughes, Michael
    Orland, Mark
    Ullah, Fauzia
    Goel, Utkarsh
    Anwer, Faiz
    Raza, Shahzad
    Mazzoni, Sandra
    Bhutani, Divaya
    Williams, Louis
    Lentzsch, Suzanne
    Samaras, Christy
    Valent, Jason
    Chakraborty, Rajshekhar
    Khouri, Jack
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 (03): : 195 - 201
12345